If modulation of tumor growth and apoptosis by miR-125b was p53-dependent, this would limit the number of patients with metastatic CaP in whom such modulation would be viewed as a therapeutic strategy, because a number of these patients' tumors have defective p53 functions. The gene discussed is TP53; the disease is neoplasm.